CT, USA and Japan — Protein Sciences Corporation, UMN Pharma Inc. and IHI Corporation announced today that they have entered into an agreement to assess the feasibility of sourcing the active ingredients of Flublok influenza vaccine from Japan. The drug substances would be manufactured at the Gifu  Plant of UNIGEN, a subsidiary of UMN Pharma in which IHI holds 50% of the common shares. UNIGEN manufactures Flublok for UMN Pharma at the 21,000L scale – ten times the scale the vaccine is manufactured in the United States. The Gifu plant has two 21,000L bioreactors and has the capacity to add six additional bioreactors.